MedTrace Logo

Possible Role of Roflumilast in Diabetic Nephropathy

NCT04755946 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2021-02-16

No results posted yet for this study

Summary

adding roflumilast to the standard therapy for diabetic nephropathy and studying the progression of many outcomes including urinary albumin to creatinine ratio, estimated GFR, biomarkers of diabetic nephropathy

Conditions

  • Diabetic Nephropathies

Interventions

DRUG

Roflumilast

adding one tablet of roflumilast 500 mcg to the standard ACEI (captopril) for diabetic nephropathy management

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Hisham M Elnahhas, Pharm D · Pharm D

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-10
Primary Completion
2021-06-10
Completion
2021-07-10

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04755946 on ClinicalTrials.gov